Cripto-1 expression in glioblastoma multiforme
| Autor: | Linda, Pilgaard, Joachim Høg, Mortensen, Michael, Henriksen, Pia, Olesen, Preben, Sørensen, Rene, Laursen, Mogens, Vyberg, Ralf, Agger, Vladimir, Zachar, Torben, Moos, Meg, Duroux |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
Adult
Aged 80 and over Male Brain Neoplasms Reverse Transcriptase Polymerase Chain Reaction Blotting Western Enzyme-Linked Immunosorbent Assay Middle Aged GPI-Linked Proteins Immunohistochemistry Neoplasm Proteins Cohort Studies Platelet Endothelial Cell Adhesion Molecule-1 Mice Cell Line Tumor Animals Humans Intercellular Signaling Peptides and Proteins Female Glioblastoma Biomarkers Neoplasm Transplantation Research Articles Aged |
| Zdroj: | Brain Pathol |
| ISSN: | 1750-3639 |
| Popis: | Human glioblastoma multiforme (GBM) is an aggressive cancer with a very poor prognosis. Cripto‐1 (CR‐1) has a key regulatory role in embryogenesis, while in adult tissue re‐expression of CR‐1 has been correlated to malignant progression in solid cancers of non‐neuronal origin. As CR‐1 expression has yet to be described in cerebral cancer and CR‐1 is regulated by signaling pathways dysregulated in GBM, we aimed to investigate CR‐1 in the context of expression in GBM. The study was performed using enzyme‐linked immunosorbent assay (ELISA), Western blotting, polymerase chain reaction (PCR) and immunohistochemistry to analyze the blood and tissue from 28 GBM and 4 low‐grade glioma patients. Within the patient cohort, we found high CR‐1 protein levels in blood plasma to significantly correlate with a shorter overall survival. We identified CR‐1 in different areas of GBM tissue, including perivascular tumor cells, and in endothelial cells. Collectively, our data suggest that CR‐1 could be a prognostic biomarker for GBM with the potential of being a therapeutic target. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|